Mark S. Levine

Mark S. Levine, listed as chief executive, has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Immunovant, Inc., Flexion Therapeutics Inc and Minerva Neurosciences, Inc. We count 37 filings; the first trade dates from 4 January 2017 and the latest from 20 November 2024.

Sales make up the whole of the open-market record (22 sales, €2.3M). The totals exclude 1 filing filed without an amount. Besides market trades, the filings include 10 share grants and 3 option exercises. In 2024 alone, the filings show no purchases and 11 sales.

The record was last updated on 22 November 2024 with an open-market sale (€88k) in Immunovant, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.